Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00999973

Enrollment

Unknown

Registered

2009-10-22

Start date

2009-09-30

Completion date

Unknown

Last updated

2009-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

In this study 126 eyes in 63 patients with moderate bilateral myopia and astigmatism between -3 and -5 (SE difference between two eyes should not be more than 0.75 and the residual corneal thickness\>350 μ ) were entered in the study. One eye went randomly under PRK with mitomycin C 0.02% in 15 min and then the other eye went under the operation without MMC. UCVA,BCVA, refractory error after the operation and the number of endothelial cells before and after the surgery would be compared in 6 months.

Interventions

DRUGMitomycin C 0.02%

DRUGPlacebo

Eligibility

Sex/Gender

ALL

Age

19 Years to 60 Years

Inclusion criteria

* 19 \< age \< 60 * Refractory error stabled for at least one year * No corneal pathology * -3 \< bilateral myopia and astigmatism \< -5 with no difference more than 0.75 between 2 eyes

Exclusion criteria

* Keratoconus * Ectatic corneal disease * Glaucoma * Corneal dystrophy * Lens changes affecting the visual acuity * Anterior or posterior uveitis * Corneal scar

Countries

Iran

Contacts

Primary ContactMohammad Ali Javadi, MD

labbafi@hotmail.com+982122585952

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026